Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.25
Previous CloseN/A
Volume134.77K
Average Volume (3M)1.00M
Market Cap
kr383.95M
Enterprise Valuekr118.51M
Total Cash (Recent Filing)kr114.83M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding320,491,640
10 Day Avg. Volume2,489,481
30 Day Avg. Volume1,003,984
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Financial LeverageThe absence of financial debt reduces refinancing exposure and interest-related pressure while preserving flexibility for research spending. This gives Isofol a stronger balance-sheet position than a similarly loss-making biotech carrying material leverage, although it does not remove its need for funding.
Positive Capital BasePositive equity and a meaningful asset base provide a financial cushion for continued clinical development and corporate operations. This supports near-term resilience and gives management more room to pursue its oncology program than a company with negative equity or an already impaired balance sheet.
Focused Oncology CandidateIsofol is focused on a defined oncology use case rather than a broad and diffuse research portfolio. A compound designed to improve established chemotherapy regimens could offer a commercially relevant development path if clinical and regulatory objectives are achieved, supporting potential future partnering or commercialization.
Bears Say
No Commercial RevenueThe absence of product revenue means Isofol has not yet demonstrated a self-funding commercial model. Future value depends heavily on successful development, regulatory approval, and eventual market adoption of its candidate, leaving revenue visibility and operating scale weak over the next several quarters.
Persistent Large LossesSustained operating and net losses indicate that the current business cannot fund itself through earnings. Continued losses can erode the capital base, constrain investment choices, and increase dependence on successful clinical execution or additional financing before the company reaches commercial profitability.
Material Operating Cash BurnHeavy recurring cash consumption requires Isofol to rely on existing reserves or external capital to maintain research and corporate activities. This creates ongoing financing dependence and makes the company more vulnerable if development spending remains high or access to new funding becomes less favorable.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.25 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr383.95M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Nov 12, 2026 which is in 11 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Aug 25, 2026. The company reported -kr0.05 earnings per share for the quarter.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report. Following the earnings report the stock price went up 1.327%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―